

tive amount of immunologically active chimeric anti-CD20 antibody
produced by ^{a transfection comprising anti-CD20 in TCAE8,} ATCC deposit number 69119;

2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody; and

3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.

20. The method of Claim ¹⁹, wherein said first, second and third therapeutically effective amount of said antibody is between 0.001 mg/kg to about 30 mg/kg.

21. The method of Claim ¹⁹, wherein said second administration period is within about seven days of said first administration period.

22. The method of Claim ¹⁹, wherein said third administration period is within about fourteen days of said first administration period.--

REMARKS

Entry of the foregoing amendments is respectfully requested. By the present amendment, Claims 19-22 are introduced which correspond to Claims 6-9 which were inadvertently cancelled upon filing of this application.